Christopher Reading

Christopher Reading

Company: BioVie Pharma

Job title: Senior Vice President Alzheimer's Programs


Modulating Metabolic Inflammation & Enhanced Brain Insulin Sensitivity to Decrease Progression of Neurodegeneration 2:30 pm

Increasing insulin sensitivity to inhibit the inflammatory ERK signalling pathway to reduce neuroinflammation by inhibition inflammation-driven insulin resistance and major pathological inflammatory cascades Reviewing phase 3 data for NE3107 as an anti-inflammatory insulin sensitizer to treat patients with mild to moderate Alzheimer’s Disease Exploring preliminary biomarker findings for NE3107 in modulating progression of neurodegenerationRead more

day: Clinical & Commercial Track PM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.